Kornimate/medical-research-clean huggingface dataset:
cerebral artery stenosis, coronary artery disease and arrhythmia

Conditions: Stroke; Coronary Artery Disease; Arrhythmia

Summary: there are many reports about the association of coronary artery disease (cad) and cerebral artery stenosis (cas), which had been proved to induce stroke and cognition decline after the revascularization including coronary bypass surgery (cabg) or percutaneous coronary intervention. perfusion defect on nuclear brain scan is also noted to correlate with these neurological complications. on the other hand, the perioperative arrhythmia and following cerebral embolism was also attributed to be one factor inducing such neurological hazards. in the patients with coexistent cad and cas (1st group), and also the patients scheduled for cabg or percutaneous coronary intervention (pci) (2nd group), we, the researchers at far eastern memorial hospital, attempted to integrate all the parameters mention above, including angiography of coronary and cerebral system, quantitative analysis of nuclear brain scan, biochemical profile, and signals of a new ambulatory device which could record the electrocardiograph (ecg) and electroencephalograph (eeg) simultaneously, in order to define the correlation between them. a chorological relation between eeg signals and ecg signals is our first target to be worked out. thereafter, we hope to establish a regression model of all involved parameters according to the relation. such a model, we believe, is essential not only to explain the post-cabg neurological complications, but to prevent them. furthermore, for the undetermined ischemic stroke patients who had no obvious culprit artery or embolism source, the paroxysmal arrhythmia had long been regarded as the cause. whether a paroxysmal atrial fibrillation, which had not been disclosed by routine ecg, could induce most of such a stroke is still not known. with this new ambulatory device which could record the electrocardiograph (ecg) and electroencephalograph (eeg) simultaneously, we want to answer the question.


Eligibility criteria:
inclusion criteria: * coronary artery stenosis \>50% and either carotid or brain artery stenosis \> 50% exclusion criteria: * creatinine \> 2.0 mg/dl * co-morbidity * er * a letter of authorization is not given

Keywords: coronary disease cerebrovascular disorders angiography cerebral ischemia intracranial atherosclerosis coronary artery disease cerebral artery stenosis percutaneous coronary balloon angioplasty coronary artery bypass surgery ischemic stroke electrocardiograph electroencephalograph nuclear brain scan cognition decline atrial fibrillation undetermined ischemic stroke
impact of diaphragmatic breathing coaching on deep inspiration breath hold reproducibility and organ protection

Conditions: Breathing, Mouth

Summary: to learn if coaching participants on diaphragmatic breathing will help participants to take larger, more reproducible breaths and feel less anxiety about their treatments.

primary objectives the primary objective is to compare the average daily shift for participant treatment for participant who have had coaching with https://www.thebreathingclass.com/cancer-center/participant versus participant who had standard clinic teaching.

Eligibility criteria:
inclusion criteria: * age \> 18 * left sided breast cancer planned for whole breast radiation or any breast cancer requiring treatment of the regional nodes * treatment planned at the mdacc mays breast radiation oncology clinic exclusion criteria: * underlying lung issues that may limit ability to achieve ideal breath hold (copd on oxygen, etc) * active pregnancy
the effect of switching to aripiprazole on heart health in overweight and obese patients with schizophrenia

Conditions: Overweight; Hyperlipidemia; Cardiovascular Diseases

Summary: this is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure. this study also examines the safety of switching to aripiprazole with respect to changes in the clinical state, preexisting or emergent side-effects, how the brain processes information and changes in social functioning and quality of life.

this is a 2-yr study proposing to examine the effects of switching subjects from conventional and atypical antipsychotic agents to aripiprazole on cardiovascular health indices in overweight and obese patients with schizophrenia or schizoaffective disorder. thirty partially remitted patients with positive and negative syndrome scale (panss) score of less than 100, who have body mass index (bmi) of 26 or higher will be switched from their existing antipsychotic to aripiprazole over 2-3 weeks period using a clinician determined cross-tapering approach.the objective of the study is to examine cardiovascular health indices such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure. this study also examines the safety of switching to aripiprazole with respect to changes in clinical state, preexisting or emergent side-effects, how brain processes information and changes in social functioning and quality of life.

Eligibility criteria:
inclusion criteria: * male and female subjects ages 18-65 years * outpatients and stable partial hospital patients * diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) diagnosis of schizophrenia or schizoaffective disorder * no psychiatric hospitalization in 30 days prior to study start * partially remitted patients with a panss score below 100 at screening * currently on a stable dose of only one antipsychotic for at least 30 days prior to study start * currently receiving a stable dose of all other psychotropic medications for at least 30 days prior to study start * bmi greater than 26 * female patients of childbearing age must be using an acceptable method of birth control for at least 1 month prior to participation in the research study and continue for at least 4 weeks after the final study visit. * ability to provide informed consent. exclusion criteria: * mental retardation * current treatment with clozapine * currently enrolled in a weight management program or receiving pharmacological treatment for weight reduction * serious or unstable medical illness * female patients who are pregnant, lactating, or plan to become pregnant during the study period * concurrently receiving treatment with ketoconazole, quinidine, carbamazepine.

Keywords: schizophrenia schizoaffective disorder aripiprazole obese overweight heart health antipsychotic heart health factors cardiovascular health indices cardiovascular health
ventilatory effect on speed of anesthesia under various inhaled anesthetics

Conditions: Pharmacokinetics of Inhaled Anesthetics

Summary: three groups of patients are going to have minor surgery under general anesthesia with inhaled anesthetics and different ventilatory setting (tidal volume: 8, 10, 12 ml/kg, respiratory rate: 10/min each). group a (sevoflurane) will use sevoflurane, group b (desflurane) will use desflurane, and group c (isoflurane) will use isoflurane. it will be observed differences among the groups for ventilatory effects on speed of induction. duration of this randomised controlled trial will be about 3 months. estimated sample size will be 36 patients(12 in each group).

no premedicant will be given. the anesthetic workstation and a circulatory circuit will be prefilled with 1.0 mac of inhaled anesthetic that will be selected randomly. * group a (n=12): sevoflurane 2.0 vol% * group b (n=12): desflurane 6.0 vol% * group c (n=12): isoflurane 1.2 vol% each group has 3 subgroups according to the ventilatory setting that will also be randomly determined. * hypoventilation: tidal volume 8 ml/kg, respiratory rate 10 /min * normoventilation: tidal volume 10 ml/kg, respiratory rate 10 /min * hyperventilation: tidal volume 12 ml/kg, respiratory rate 10 /min patients will be preoxygenated with 100% oxygen (5 l/min) for 5 minutes under pulse oximeter, ekg, and noninvasive blood pressure monitoring. bispectral index (bis) monitor will be applied. the induction of general anesthesia will start with propofol (2 mg/kg), rocuronium (0.8 mg/kg) and remifentanil infusion (0.1 mcg/kg/min). the size of a tracheal tube will be 7.5 mm (id) for male, 7.0 mm (id) for female. after intubation, anesthesia workstation will be connected to the tracheal tube. ventilation will start, and that point will be time 0. during 720 seconds, inspiratory (pigas) and end-tidal concentration of inhaled anesthetics (etgas), end-tidal partial pressure of carbon dioxide, and bis will be measured at time 0, 30, 60, 90, 120 ,150, 180, 240, 300, 360, 480, 600, and 720 seconds. mean blood pressure and heart rate will also be recorded every 2 minutes. fresh gas flow will be kept at 6 l/min with 100% oxygen. the fraction of etgas/pigas will be analyzed with nonlinear mixed effects modeling. estimated sample size will be 36 patients (12 in each group, 4 in each ventilatory settings).

Eligibility criteria:
inclusion criteria: * asa ps i, ii * age: 20-60 years male and female * elective schedule with minor surgery * bmi \< 30 exclusion criteria: * patients with pulmonary, cardiac, endocrinal, neuromuscular and neurological diseases or past history * upper airway anomaly or deformity * asa ps iii or higher * pregnant women * bmi \>= 30

Keywords: anesthetic induction desflurane isoflurane sevoflurane ventilation
biological and clinical efficacy of shingrix in patients with cll

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; CLL-like MBL; Varicella-zoster Virus Reactivation

Summary: this is a biological study. patients who are eligible to receive shingrix through the italian national health system will be invited to participate in the study. according to aifa indication, the two doses of vaccine will be administered 4-8 weeks apart. blood samples will be collected prior to the first vaccine dose (i.e. within the time frame of 3 months prior to the first dose) and 1, 6, 12, 24 and 36 months after the second vaccine dose to evaluate the serological response of shingrix.

this is a multi-centre, prospective study, performed on biological samples only. patients who are eligible to receive shingrix through the italian national health system will be invited to participate in the study. according to aifa indication, the two doses of vaccine will be administered 4-8 weeks apart. blood samples will be collected prior to the first vaccine dose (i.e. within the time frame of 3 months prior to the first dose) and 1, 6, 12, 24 and 36 months after the second vaccine dose to evaluate the serological response of shingrix. all protocol procedures (including clinical assessment and blood draws) will be performed during regular follow-up visits according to clinical practice. no additional invasive/dangerous/painful procedures will be required by the study.

Eligibility criteria:
inclusion criteria: * diagnosis of cll or small lymphocytic lymphoma (sll) or cll-like mbl according to iwcll guidelines. patients must belong to one of the following subgroups: * group a: patients with mbl or previously untreated early-phase cll/sll (binet stage a or rai stage 0), with no clear signs of disease progression; * group b: patients with active or symptomatic disease according to iwcll guidelines or with advanced binet or rai stages receiving both the first and second vaccine doses before treatment initiation; * group c: patients with cll/sll receiving targeted drugs (i.e. ibrutinib/acalabrutinib-based treatment or venetoclax-based treatment) for at least 6 months prior to the administration of the first vaccine dose. * age 18 years or older * eligible to receive shingrix according to clinical indication and free of charge through the italian national health system * life expectancy \>6 months * no active, symptomatic herpes zoster infection or varicella-zoster virus reactivation within 12 months prior to vaccination * no prior exposure to shingrix * able and willing to provide written informed consent and to comply with the study protocol procedures exclusion criteria: * female patients who are currently in pregnancy or are willing to be pregnant * any uncontrolled active systemic infection * intravenous immunoglobulin (ivig) administration within 3 months prior to vaccination * concomitant use of radiotherapy or chemotherapy * hereditary or acquired immunodeficiency syndrome unrelated to cll * chronic use of immunosuppressive medications given for indications that are not cll-related
study on correlation between vascular et-1 and adiponectin in pediatric obesity

Conditions: OBESITY; Endothelial Dysfunction; Insulin Resistance

Summary: the aim of this study is to explore whether and how high circulating levels of endothelin-1 (et-1) in obese and overweight children may contribute to impair adiponectin (ad) production, release and vascular activity


Eligibility criteria:
inclusion criteria: * children will be enrolled into lean, overweight or obese groups based on body mass index (bmi) calculated according to standard methods. international standards for sex-and age-specific bmi centiles for subjects aged 2-18 years will be used. the 95th centile of bmi reference is the cut off point for childhood obesity. overweight and obese children are defined as those with a bmi higher than the centile curves. exclusion criteria: * presence of renal, liver and/or cardiovascular diseases; * hypertension; * metabolic and/or endocrine disorders; * genetic syndromes; * histories of chronic allergies, acute infectious or inflammatory diseases during the last 3 months preceding the study
plaque stabilization and restoration by bioresorbable vascular scaffold

Conditions: Vulnerable Plaque

Summary: the aim of the study is to assess if implantation of a bioresorbable vascular scaffold (bvs) for intermediate coronary lesions with morphological signs of vulnerable plaque in patients prone for acute coronary syndromes (acs) will stabilize the plaque, improve natural vasomotion and increase vascular diameter.


Eligibility criteria:
inclusion criteria: * symptomatic patients between the age of 18 and 80 years * morise risk score of ≥9 (intermediate or high risk) but no proven ischemia (no positive troponin or st-elevation) * intermediate coronary lesion on ct scan (50-70% based on ct estimate) and a plaque with at least two of the following vulnerability criteria: napkin ring sign, positive remodeling, low attenuation and spotty calcification * ffr negative lesion at coronary angiogram * vessel diameter ≥2.5 mm on visual estimate * gfr ≥ 45ml/min/1.73m². exclusion criteria: * high calcium score on ct scan preventing adequate evaluation of the coronary lesion. * lesions located in a coronary vessels previously stented. * lesions located at a bifurcation * lesions involving an epicardial side branch ≥2 mm in diameter by visual assessment * the presence of thrombus or another clinically significant stenosis in the target vessel. * left main (\>50%) or known three vessel disease. * patients presenting with acute myocardial infarction, unstable arrhythmias, or patients who have a left ventricular ejection fraction \<30% * intolerance to aspirin, clopidogrel, prasugrel, ticagrelor, heparine or everolimus and known true anaphylaxis to prior contrast media or known bleeding diathesis or known coagulopathy. * planned elective surgical procedure necessitating interruption of dual antiplatelet therapy during the first 6 months after inclusion. * history of stent thrombosis * malignancies or other comorbidity with a life expectancy of less than one year or that may result in protocol noncompliance * pregnancy (present, suspected or planned) or positive pregnancy test (in women with childbearing potential a negative pregnancy test is mandatory)
effectiveness and tolerability of long-acting nifedipine gastrointestinal therapeutic system in chronic kidney disease with uncontrolled hypertension patients, a prospective, multicenter, observational study

Conditions: Hypertension

Summary: chronic kidney disease (ckd) and hypertension are two closely related common chronic diseases that have serious implications to human health. hypertension is a major cause for progression of renal disease and a risk factor for cardiovascular disease (cvd). control of blood pressure (bp) to target is now considered to be the main goal in the treatment of patients with ckd. in clinical practice, it is difficult for ckd patients with hypertension to achieve systolic bp (sbp) or diastolic bp (dbp) goal; oftentimes, calcium channel blocker (ccb) class of drugs, for example, nifedipine gastrointestinal therapeutic system (gits), is used in such patients. previous data have demonstrated nifedipine to be having a significant dose-response relationship; that is, nifedipine 60 mg provided better bp reduction than 30 mg. however, there are limited studies that have evaluated the efficacy and tolerability of nifedipine gits 60 mg in chinese ckd patients with hypertension. hereby, the objective of this study was to evaluate the effectiveness and tolerability of nifedipine gits 60 mg treatment in a large cohort of ckd patients with uncontrolled hypertension.


Eligibility criteria:
inclusion criteria: * male and female patients aged 18-70 years * patients diagnosed with ckd (estimated glomerular filtration rate (egfr) \>15 ml/min/1.73 m\*2) and hypertension without dialysis/replacement therapy * patients with uncontrolled hypertension (office sbp ≥140 mmhg and dbp ≥ 80 mmhg) who have received renin-angiotensin system inhibitors (rasi) treatment or have not received rasi treatment because of any contraindications * patients who haven't received nifedipine gits 60 mg (once per day) previously * patients for whom the decision to initiate treatment with nifedipine gits 60 mg was made as per the investigator's routine treatment practice * signed informed consent * no participation in an investigational program with interventions outside of routine clinical practice exclusion criteria: * have a contraindication to nifedipine gits according to the approved prescribing information * patients participating in an investigational program with interventions outside of routine clinical practice
the treatment advocacy program

Conditions: HIV

Summary: the purpose of the study is to test the efficacy of tap, a behavioral intervention, in improving sexual safety and treatment adherence among gay and bisexual men infected with hiv. it is hypothesized that those who are in the intervention group will report reductions in unprotected sex with hiv-negative and unknown-status partners; and will show stricter adherence to their treatment regimens, compared to the individuals in the standard-of-care, control group.


Eligibility criteria:
inclusion criteria: * hiv+ men who have sex with other men, age 18 or over, in hiv care at one of the collaborating clinics, any sexual contact within the previous six months. exclusion criteria: * self-reported low likelihood of remaining in treatment or in the study location for 12 months, inability to comprehend the consent quiz administered during the consent and enrollment visit, or unwilling to provide required locator information
acupuncture therapy in patients with subacromial impingement syndrome

Conditions: Acupuncture; Subacromial Impingement Syndrome

Summary: shoulder pain is highly prevalent within general population, and shoulder impingement syndrome (sis) is a common cause of shoulder pain. a small number of clinical and methodologically diverse trials have been published recently which show little evidence to support or refute the use of acupuncture for shoulder pain. some researchers concluded, there is a need for further well-designed clinical trials. our aim in this study is to investigate the effect of acupuncture treatment on pain, range of motion, functionality and quality of life in patients diagnosed with subacromial impingement syndrome as a result of clinical and radiological tests.

a randomized, prospective, double-blinded, placebo-controlled trial will be conducted. patients diagnosed with shoulder impingement syndrome will be divided into two groups (acupuncture and placebo acupuncture) the evaluation will be performed at treatment initiation and at the end of the treatment and 1 month after treatment initiation.all patients will be evaluated by the same physiatrist who are blinded to the randomization process and treatment protocols.primary outcome is pain which will be evaulated with visual analogue scale (vas) for rest, activity, and sleep-disturbing. secondary outcomes are shoulder range of motion in all groups will be evaluated with goniometer, shoulder function which will be evaulated with the shoulder pain and disability index (spadi) and the disabilities of the arm, shoulder and hand score (quickdash) and quality of life in all groups will be evaluated with the western ontario rotator cuff index (worc).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of subacromial impingement syndrome * age range from 20-65 years * pain vas ≥ 4 * shoulder impingement symptoms lasting at least 6 weeks exclusion criteria: * presence of other shoulder pathologies * previous applications of physiotherapy and injection of hyaluronic acid and/or corticosteroid during the preceding 3 months; * presence of cervical pain or other conditions such as fibromyalgia confusing the clinical picture * presence of malignancy, blood disorder, neurologic, motor, and/or sensory deficit in the upper extremity; * pregnancy, * local anesthetic allergy * previous acupuncture treatment * history of deformities, fractures, or surgery of the shoulder
prenatal cytogenetic diagnosis by array-based copy number analysis

Conditions: Genetic Diseases

Summary: the main objective of the multi-centered collaborative study is to evaluate the accuracy, efficacy and clinical advantages of prenatal diagnosis using microarray analysis as compared with conventional karyotyping.

specifically, the aims are as follows: 1. demonstrate the performance of microarray analysis as a clinical method for prenatal cytogenetic diagnosis with regard to: 1. accuracy in the detection of the common autosomal and sex chromosomal aneuploid (trisomies, 13,18,21, 45,x, 47,xxy, etc.) 2. ability of microarray to diagnose less common, but clinically significant, cytogenetic aneusomies (e.g. digeorge, williams, smith- magenis, prader-willi syndrome, etc.) currently not detected by conventional karyotype. 3. evaluation of the utility of microarray in specific clinical scenarios such as ultrasound detection of congenital anomalies and fetal growth disorders. 2. evaluate the appropriate construction of prenatal diagnostic microarray devices to allow maximal detection of clinically relevant information with minimal detection of unexpected and difficult to interpret findings which have no clinical significance but might provoke patient anxiety. 3. evaluate the feasibility and cost-effectiveness of using microarrays as a primary prenatal diagnostic tool. 4. evaluate approaches to integrate microarray into clinical prenatal cytogenetic diagnostic practice. 5. develop a prenatal diagnostic tissue repository (tdr) to facilitate the further development of microarray technology. this will be used to investigate the molecular etiologies of specific fetal anomalies and to test newer technologies, such as higher resolution microarrays.

Eligibility criteria:
inclusion criteria: 1. singleton pregnancy having either chorionic villus sampling in the first trimester or an amniocentesis procedure at or after 16 weeks of gestation performed for prenatal cytogenetic diagnosis 2. karyotyping to be performed at genzyme genetics cytogenetics laboratory 3. trained study personnel available 4. presenting at pre-specified sites using genzyme genetics for routine prenatal diagnostic services exclusion criteria: 1. unavailability of one or both biologic parents to provide blood sample (e.g. egg or sperm donor, non-paternity) 2. patient refusal to allow follow-up through the neonatal period and up to age two if selected 3. participation in the study in a previous pregnancy 4. insufficient sample for microarray assay

Keywords: microarray